Macquarie Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Macquarie Group’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-124	Closed	-$79K	–	2186
2022 Q3	$79K	Sell	124 -227	-65%	-$45.9K	﹤0.01%	1832
2022 Q2	$44K	Hold	351	–	–	﹤0.01%	2087
2022 Q1	$45	Hold	351	–	–	﹤0.01%	2176
2021 Q4	$46K	Hold	351	–	–	﹤0.01%	2185
2021 Q3	$43K	Hold	351	–	–	﹤0.01%	2276
2021 Q2	$40K	Hold	351	–	–	﹤0.01%	2202
2021 Q1	$42K	Sell	351 -107	-23%	-$12.1K	﹤0.01%	2120
2020 Q4	$47K	Hold	458	–	–	﹤0.01%	2054
2020 Q3	$35K	Hold	458	–	–	﹤0.01%	2029
2020 Q2	$51K	Buy	+458	New	+$39.8K	﹤0.01%	1925

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group's KRTX Position: Q4 2022 in Review

Macquarie Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 124 shares — an estimated $79K sold.

Macquarie Group first reported a position in KRTX in Q2 2020 and held it in 10 quarters. The position peaked at $79K in Q3 2022. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

Macquarie Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 124 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $79K.
Macquarie Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Macquarie Group's Karuna Therapeutics, Inc. Common Stock position peaked at $79K in Q3 2022.
248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.